Abstract:e16144 Background: Pathological complete response (CR) and major pathological response (MPR) are associated with long-term survival after neoadjuvant/conversion surgery of HCC. The relationship between imaging and histopathological evaluations of response to combined TKI plus anti-PD-1 antibody treatment is unclear. Methods: This retrospective analysis included 23 patients with an initial diagnosis of unresectable HCC who underwent resection after combined TKI/anti-PD-1 antibody treatment between March 2019 and December 2020 at Zhongshan Hospital of Fudan University. MRI was performed before and after treatment and objective response rate (ORR; CR or partial response [PR]) was evaluated using RECIST 1.1 and mRECIST by investigator assessment (INV) and independent imaging review (IIR). Histopathological response was evaluated in resected tumor tissue using residual viable tumor (RVT; RVT area/total tumor bed surface area under 100X microscopy). MPR was defined as <10% RVT. The relationship between radiological reduction in tumor size and MPR was investigated using a receiver operating characteristic (ROC) curve. Results: Patients had a median age of 54.0 years, 91% were male and the average pre-treatment tumor diameter was 11.5±4.6 cm. Three had Barcelona Clinic Liver Cancer (BCLC) Stage A disease (China Liver Cancer Stage [CNLC] Ib, n=3), six had BCLC Stage B (CNLC IIa, n=1 and IIb n=5) and 14 had BCLC Stage C (CNLC IIIa, n=10 and IIIb, n=4). Patients received lenvatinib (n=19) or apatinib (n=4) plus anti-PD-1 antibodies (pembrolizumab [n=5], sintilimab [n=5], camrelizumab [n=10], treprizumab [n=2] or nivolumab [n=1]) followed by resection. Radiological responses are summarized in Table. An MPR or pathologic CR was achieved by 52.2% (12/23) and 39.1% (9/23) of patients, respectively. A correlation was observed between radiological responses using RECIST 1.1 and mRECIST and MPR (Fisher’s exact test; P=0.089 and 0.037, respectively). Using RECIST 1.1, the optimum diagnostic cutoff for MPR was a 26% reduction in tumor size, by both INV (area under ROC (AUC)=0.780, 95% CI: 0.580–0.981, sensitivity 83.3%, specificity 72.7%) and IIR (AUC=0.739, 95% CI: 0.527–0.951, sensitivity 75.0%, specificity 72.7%). Using mRECIST, the optimum cutoff for MPR was a 78% reduction in tumor size by INV (AUC=0.746, 95% CI: 0.538–0.954, sensitivity 58.3%, specificity 90.9%) and IIR (AUC=0.742, 95% CI: 0.532–0.953, sensitivity 66.7%, specificity 81.8%). Conclusions: Radiological response showed a degree of correlation with MPR in patients with advanced HCC receiving combined TKI and anti-PD-1 antibody therapy. Therefore, imaging evaluation may be used to predict a pathological response and further guide clinical treatment decisions. Response rates (n=23).[Table: see text]

Prediction of therapeutic response of advanced hepatocellular carcinoma to combined targeted immunotherapy by MRI

Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib Plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study

Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE

MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma after Combined Lenvatinib and Anti-Pd-1 Antibody Therapy.

Radiomics Analysis Based on Contrast-Enhanced MRI for Prediction of Therapeutic Response to Transarterial Chemoembolization in Hepatocellular Carcinoma

Multiparametric MRI-based Machine Learning Radiomics for Predicting Treatment Response to Transarterial Chemoembolization Combined with Targeted and Immunotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter Study

Radiomic Analysis Based on Magnetic Resonance Imaging for Predicting PD-L2 Expression in Hepatocellular Carcinoma

Predicting the Outcome of Transcatheter Arterial Embolization Therapy for Unresectable Hepatocellular Carcinoma Based on Radiomics of Preoperative Multiparameter MRI

Contrast-enhanced MRI Could Predict Response of Systemic Therapy in Advanced Intrahepatic Cholangiocarcinoma.

MRI radiomics to monitor therapeutic outcome of sorafenib plus IHA transcatheter NK cell combination therapy in hepatocellular carcinoma

Radiological response as a predictor of pathological response to combined tyrosine kinase inhibitor (TKI) and anti-PD-1 antibodies in hepatocellular carcinoma (HCC).

Diagnostic Model for Proliferative HCC Using LI‐RADS: Assessing Therapeutic Outcomes in Hepatectomy and TKI‐ICI Combination

Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma

The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody

Prediction of PD-L1 expression in unresectable hepatocellular carcinoma with gadoxetic acid-enhanced MRI

Preoperative MRI-based multiparametric model for survival prediction in hepatocellular carcinoma patients with portal vein tumor thrombus following hepatectomy

Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma

MRI-Radiomics Prediction for Cytokeratin 19-Positive Hepatocellular Carcinoma: A Multicenter Study

Development and validation of survival prediction models for patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus tyrosine kinase inhibitors

Multiparametric MRI combined with clinical factors to predict glypican-3 expression of hepatocellular carcinoma

Baseline hepatobiliary MRI for predicting chemotherapeutic response and prognosis in initially unresectable colorectal cancer liver metastases